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ABSTRACT: Objective—The study was undertaken to investigate the effects of a commonly used ovarian 
stimulation regimen on gonadotropin levels. Methods—The behavior of follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), and human chorionic gonadotropin (hCG) was studied after intramuscular (i.m.) 
and intravenous (i.v.) human menopausal gonadotropin (hMG) administration. Six female volunteers partici­
pated in the study. During pituitary suppression with a gonadotropin-releasing hormone (GnRH) agonist 
(Buserelin), a single dose of hMG (150 IU) was injected i.m, or iv., in a cross-over design with an interval of 2 
weeks. Blood samples were collected frequently after the injection. Serum concentrations of FSH, specific LH 
and hCG were determined. Results—After i.m. administration of hMG, a peak FSH concentration of 7. 4± 1.3 
U/L was reached after 8 (6-24) hours, with a subsequent decrease. At 0.5 hour after i.v. administration, peak 
FSH values of 30.5 ± 5.6 U/L were obtained, followed by a decrease to baseline levels within 48 hours. Exoge­
nous LH and hCG were hardly detectable after i.m. administration of hMG. One-half hour after i.v. injection 
of hMG, a small increase in specific LH levels to 6.7 ± 2.6 U/L was shown, followed by a decline. hCG con­
centrations increased after i.v. hMG administration to 7.6 ±1.6 U/L. Int J Fertil 40(2):86-91, 1995
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INTRODUCTION
ONADOTROPIN PREPARATIONS
have been used in clinical practice for 
many years, mainly for stimulation of fol­
licular growth and induction of ovulation 
[1,2]. These preparations contain follicle-stimulat­
ing hormone (FSH) and luteinizing hormone (LH) 
activities. FSH and LH are isolated primarily from 
urine of postm enopausal women. Since the
amount of LH is not sufficient to reach an FSH/LH 
ratio of 1, human chorionic gonadotropin (hCG), 
purified from urine of pregnant women, may be 
added in small amounts to the preparation to reach 
the necessary LH in vivo bioactivity [3].
Although many women have been treated with 
these gonadotropin preparations for over 25 years, 
relatively little is known about their kinetic behav­
ior after injection: how high are the peak concen­
trations and how fast are they reached; what is the
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decrease rate after injection? Previously published 
studies reported on pharmacokinetics of endoge­
nous gonadotropins [4,5] or gonadotropins purified 
from human pituitaries [6,7], Hormones isolated 
from urine, however, might exert very different 
kinetic properties [8]. Two of the studies on phar­
macokinetics of urinary gonadotropins reported on 
males [9,10], while Sharma et al [11] investigated 
the pharmacokinetics of a purified FSH preparation 
in women w ith suppressed pituitary function. 
Diczfalusy and Harlin [12] also investigated the 
pharmacokinetics of gonadotropins in women after 
a single intravenous (i.v.) or repeated intramuscular 
(i.m.) administration, but they did not suppress the 
endogenous gonadotropin activity, which compli­
cated the estimation of the half-life of LH. The 
effect of administration of human menopausal 
gonadotropin (hMG) on serum hCG concentrations 
has never been reported.
In clinical practice, women undergoing ovarian 
stimulation treatment are routinely given daily 
i.m. injections of hMG, often during pituitary sup­
pression by a gonadotropin-releasing hormone 
(GnRH) agonist [13]. Recently, pulsatile i.v. admin­
istration of hMG has been used for ovarian stimu­
lation; this would mimic the physiological release 
of pituitary hormones [14,15].
The present study investigates for the first time 
the effect on serum FSH, LH and hCG levels of a 
single i.m. and i.v. administration of hMG in a 
group of women during pituitary suppression.
METHODS 
Study Design
Six healthy female volunteers participated in the 
study. They all had regular menstrual cycles of 
26-30 days, two ovaries, normal early follicular 
levels of FSH, LH, prolactin, testosterone and thy­
roxin, and had not used sex steroids in the 3 
months prior to the study. The age of the women 
varied from 28 to 35 years; their median height was 
1.68 m (1.65-1.73), and their median weight, 63 kg 
(55-95). The body mass index varied from 19.5 to 
35.0 mg/m2, (median value 21.5 kg/m2). The study 
was approved by the Ethical Committee of the hos­
pital. Written informed consent was given.
On day 21 of the cycle, intranasal administration 
of the GnRH agonist Buserelin (Suprefact®, Hoechst
Holland N.V., Amsterdam) was started at a dose of 
300 pg three times a day. If the serum estradiol con­
centration on the tenth day of Buserelin administra­
tion was below 500 pmol/L, pituitary suppression 
was considered sufficient. If the estradiol level was 
above 500 pmol/L, the estradiol determination was 
repeated two or three days later until the required 
low concentration was reached. Buserelin was con­
tinued during the entire study period.
Between 8:00 and 9:00 a .m . on the day after the 
estradiol level was below 500 pmol/L, 150 IU hMG 
(Humegon®, Organon Int. B.V., Oss) was injected 
intramuscularly or intravenously. The first hMG 
administration was i.m. in three women and i.v. in 
the other three women. Two different batches of 
Humegon were used, with similar FSH (82 IU per 
ampule) and LH in vivo bioactivity (66 and 61 IU 
per ampule, respectively). Immediately before the
hMG injection, at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 
96 hours, and 1 week after hMG administration, 
blood samples were collected. The samples were 
centrifuged within 15 minutes (five minutes at 
2,500 g) and the sera were stored at 
-20°C until assayed. After a washout period of 2 
weeks, a second injection of 150 IU hMG was given 
using the other route of administration. The same 
protocol for the collection of serum samples was 
performed. One week after the second hMG injec­
tion Buserelin administration was discontinued.
Assays
The serum estradiol concentration on the tenth 
day of buserelin treatment was determined by a 
time-resolved fluoroimmunoassay (DELFIA®, Wal- 
lac Oy, Turku, Finland). The limit of 500 pmol/L 
was chosen because of the low sensitivity of the 
assay in the range from 150 to 500 pmol/L. The 
estradiol concentration immediately before the 
first hMG injection was measured retrospectively 
by a more sensitive radioimmunoassay [16].
Serum concentrations of FSH, specific LH and 
hCG were measured by applying time-resolved flu- 
oroimmunoassays (DELFIA). These tests are solid 
phase, two-site assays in which two monoclonal 
antibodies are directed against two separate anti­
genic determinants on the hormone. The assays 
detect only intact molecules. Serum samples are 
first reacted with immobilized monoclonal anti­
bodies directed against a specific antigenic site on
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the (3-subunit of the hormone. Europium-labeled 
antibodies directed against a specific antigenic site 
on the a- or f}-subunit are then reacted with the 
molecule, already bound to the solid phase anti­
body. After dissociation of the europium ions from 
the labeled antibody, the amount of fluorescence is 
measured.
The assay for FSH had a detection limit of 0.05 
U/L, with an intra-assay and inter-assay variation 
of less than 5%. The assay for specific LH had a 
cross-reactivity with hCG of less than 1.5%. The 
detection limit for specific LH was 0.05 U/L; the 
intra-assay variation was less than 6%, the inter­
assay variation less than 8%. The hCG assay had a 
cross-reactivity for LH of less than 0.5%. The 
detection limit was 0.5 U/L, the intra-assay varia­
tion less than 10%, the inter-assay variation less 
than 11%.
Statistics
All data are presented as mean values with the 
standard error of the mean.
RESULTS
The mean period of Buserelin administration 
before reaching the estradiol limit of <500 pmol/L 
was 13 ± 2.9 days. The mean estradiol concentra­
tion immediately before the first hMG injection, as 
measured by radioimmunoassay, was 203 ±107  
pmol/L. One woman completed the first series of 
blood samplings after i.v. hMG administration; but 
did not wish to continue the study. Therefore data 
were obtained from six women after i.v. adminis­
tration and from five women after i.m. administra­
tion. The wash-out period between the two routes 
of administration appeared to be sufficiently long.
FSH concentrations after i.m. and i.v. adminis­
tration of a single dose of hMG are presented in 
Figure 1 and Table I. The mean FSH concentration 
at 48 hours after both i.m. and i.v. injection did not 
differ from the FSH concentration before injection 
(4.6 ± 0.9 U/L and 3.6 ± 0.6 U/L, respectively).
Specific LH concentrations in serum, measured 
without the cross-reactivity of hCG, after i.m. and 
i.v. administration of a single dose of hMG are pre­
sented in Figure 2 and Table I. In the first half-hour 





FIG. 1. Serum FSH concentrations in five women after 
i.m. injection (A) and in six women after i.v. injection 
(B) of 150IU hMG, during GnRH agonist administration.
fered: in two women, LH concentrations increased, 
whereas in three women no increase was seen. 
After the first half-hour a decrease of LH concen­
trations was present in all women, until six hours 
after injection, when LH concentrations returned 
to baseline values. Following the initial rise of LH 
concentrations after i.v. injection to 6.7 ± 2.6 IU/L, 
a decrease to 2.1 ± 1.0 U/L at four hours after injec­
tion was present. After this decrease, LH concen­
trations returned to baseline levels
After i.m. administration of hMG, hCG concen­
trations hardly exceeded the detection limit of the
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FIG. 2. Specific LH concentrations in serum in five 
women after i.m. injection (A) and in six women after i.v. 
injection (B) of 150 IU hMG, during GnRH agonist 
administration.
assay. Serum hCG concentrations after i.v. admin­
istration are presented in Table I.
A
DISCUSSION
After i.m. administration of hMG, serum FSH lev­
els showed a smaller and more prolonged increase 
than after i.v. administration. The probable expla­
nation is the formation of an intramuscular depot 
of hMG, with a gradual release into the systemic 
circulation. Since the absorption process from the
intramuscular depot would continue during the 
elimination of the previously absorbed amount of 
hMG, the decrease of FSH levels after i.m. adminis­
tration was slower than after i.v. administration.
Results of previous studies in male subjects by 
Mizunuma et al [9] and by Jockenhôvel et al [10] 
were in accordance with our results in females. 
Mizunuma et al administered a single i.m. dose of 
hMG and urinary FSH. They described a peak FSH 
value seven to eight hours after injection and half- 
lives of 36 and 32.6 hours, respectively. Jockenhôv­
el et al described a peak FSH value 10 hours after 
the i.m. administration of urinary FSH, and a half- 
life of 24.6-36.2 hours. Sharma et al [11] and Dicz- 
falusy and Harlin [12] performed studies in women. 
Sharma et al determined FSH after a single i.m. 
injection of purified urinary FSH during Buserelin 
administration. They observed peak FSH levels 
between 6 and 18 hours after injection, and a 
decline of FSH starting 24 hours after injection. 
Diczfalusy and Harlin measured FSH after a single 
i.v. administration of hMG without pituitary sup­
pression. They observed a rapid decay with a half- 
life of 1.6 hours and a slow phase with a half-life of 
11 hours. Our study and those of Jockenhôvel et al 
and Sharma et al differ from the other studies men­
tioned in the application of a more sensitive assay
We were able to differentiate between the LH and 
hCG components in hMG by applying two specific 
assays. Diczfalusy and Harlin [12] mentioned the 
difficulty in interpreting serum LH concentrations 
because of the presence of endogenous LH and the 
relatively low amount of administered LH, We met 
the same problem in our study, despite the adminis­
tration of Buserelin. The measured LH activity after
i.m. hMG administration was probably merely 
endogenous LH. The decrease of specific LH con­
centrations shortly after i.m. injection was previ­
ously described by Diczfalusy and Harlin [12]. 
Anderson et al [17] saw a decrease in serum LH lev­
els after an i.m. injection with purified FSH, but 
not after an i.m. hMG injection. The most likely 
explanation for this decrease is a negative feedback 
mechanism within the hypothalamo-pituitary-ovar- 
ian axis. Exogenous FSH and LH activity may have 
stimulated the ovaries to produce estradiol, which 
in turn had a suppressive effect on the pituitary 
FSH and LH secretion [18]. The decrease of endoge­
nous FSH could not be seen in the serum levels 
because of the presence of exogenous FSH. We con­
sider the second LH rise in several women to be not
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TABLE I
Mean basal (C0) and maximal (Ctrmx) concentrations of serum FSH, specific LH 
and hCG (with standard error) after a single intramuscular (i.m.) or intravenous 
(LvJ administration of 150IU human menopausal gonadotropin (hMG), in 
six healthy women during pituitary suppression with Buserelin.
Co tmqx fllOVlïS) n-J [.max
Serum FSH i.m. 3.8 ± 1.1 U/L 8 (6-24) 7 A  ± 1.3 U/L
i.v. 4.4 ± 1.5 U/L 0.5 30.5 ± 5.6 U/L
Serum LH spec i.m. 3.7 ±1.8 U/L 96 (0.5-168) 5.2 ± 2.7 U/L
i.v. 3.5 ±1.7 U/L 0.5 (0.5-96) 7.0 ± 2.6 U/L
Serum hCG i.m. <0.5 U/L
i.v. <0.5 U/L 0.5 (0.5-1) 7.6 ± 1.6 U/L
¿max = median interval post-injection before reaching peak value (range in parentheses).
a real rise but rather the return to baseline levels. 
Several other authors investigated the pharmacoki­
netics of LH. Yen et al [4] described a double-expo- 
nential disappearance curve of serum LH following 
surgical hypophysectomy in two women; Kjeld et al 
[7] determined a half-life of 2.3 hours after i.v. infu­
sion of pituitary LH in males. Their study designs 
were not comparable with ours, and differed more 
from ordinary clinical practice.
In other studies, the pharmacokinetics of hCG 
were investigated. Damewood et al [19] studied the 
disappearance of hCG administered i.m. In our 
study, the dose of hCG in hMG was too low to 
detect hCG in serum after i.m. injection. Wide et al 
[20] administered hCG intravenously and measured 
serum hCG concentrations by RIA. They calculated 
a half-life of 6-10 hours, which is in agreement 
with our results.
In conclusion, we have described for the first 
time the different patterns of serum FSH levels over 
time after a single i.m. or i.v. injection of hMG dur­
ing pituitary suppression. LH and hCG were hardly 
detectable after i.m. administration, but showed a 
demonstrable increase after i,v. injection.
REFERENCES
ACKNOWLEDGMENT
We would like to thank Dr. Bart A. Bastiaans and 
Dr. Chris M.G. Thomas for critically reading the 
manuscript and Dr. George F. Borm for his statisti­
cal advice.
1. Gemzell CA, Diczfalusy E, Tillinger G: Clinical effect 
of human pituitary follicle-stimulating hormone 
(FSH). J Clin Endocrinol Metab 18:1333-1348, 1958.
2. Schwartz M, Jewelewicz R: The use of gonadotropins 
for induction of ovulation. Fertil Steril 35:3-12, 1981.
3. Yemer HM, Sanders ALM: Amounts of LH and hCG 
similar in two commercial hMG preparations. Pre­
sented at the Xlllth World Congress on Fertility and 
Sterility, Marrakesh, October 1-6, 1989 (abstr).
4. Yen SSC, Llerena O, Little B, et al: Disappearance 
rates of endogenous luteinizing hormone and chorion­
ic gonadotropin in man. J Clin Endocr 28:1763-1767, 
1968.
5. Yen SSC, Llerana LA, Pearson OH, et al: Disappear­
ance rates of endogenous follicle-stimulating hor­
mone in serum following surgical hypofysectomy in 
man. ƒ Clin Endocr 30:325-329, 1970.
6. Amin HK, Hunter WM: Human pituitary follicle 
stimulating hormone: distribution, plasma clearance 
and urinary excretion as determined by radioim­
munoassay. f  Endocr 48:307-317, 1970.
7. Kjeld JM, Harsoulis P, Kuku SF, et al: Infusions of 
hFSH and hLH in normal men. Acta Endocrinol 
81:225-233, 1976.
8. Harlin }, Khan SA, Diczfalusy E: Molecular composi­
tion of luteinizing hormone and follicle-stimulating 
hormone in commercial gonadotropin preparations. 
Fertil Steril 46:1055-1061, 1986.
9. Mizunuma H, Tagaki T, Honjyo S, et al: Clinical phar­
macodynamics of urinary follicle-stimulating hor­
mone and its application for pharm acokinetic 
simulation program. Fertil Steril 53:440-445, 1990.
IntJ Fertil 40
Hormonal Patterns After hMG injection ■ 91
10. Jockenhövel F, Fingscheidt U, Khan SA, et al: Bio- and 
immuno-activity of FSH in serum after intramuscular 
injection of highly purified urinary human FSH in 
normal men. Clin Endocrinol 33:573-584, 1990.
11. Sharma V, Williams J, Collins W, et al: Studies on the 
measurement and pharmacodynamics of human folli­
cle-stimulating hormone. Fertil Steril 47:244-248, 
1987.
12. Diczfalusy E, Harlin J: Clinical-pharmacological stud­
ies on human menopausal gonadotrophin. Human 
Reprod 3:21-27, 1988.
13. Neveu S, Hedon B, Bringer J, et al: Ovarian stimula­
tion by a combination of a gonadotropin-releasing 
hormone agonist and gonadotropins for in vitro fertil­
ization. Fertil Steril 47:639-643, 1987.
14. Ho Yuen B, Pride SM, Burch Calligari P, et al: Clinical 
and endocrine response to pulsatile intravenous 
gonadotropins in refractory anovulation. Obstet 
Gynecol 74:763-7688, 1989.
15. Edelstein MC, Brzyski RG, Jones GS, et al; Ovarian 
stimulation for in vitro fertilization in low-responder 
patients using pulsatile intravenous follicle stimulat­
ing hormone. J In Vitro Fertil Embryo Transf 
7:275-279, 1990.
16. Thomas CMG, Corbey RS, Rolland R: Assessment of 
unconjugated oestradiol and progesterone serum lev­
els throughout pregnancy in normal women and in
women with hyperprolactinaemia who conceived 
after bromocryptin treatment. Acta Endocrinol (Kbh) 
86:405-414, 1977.
17. Anderson RE, Cragun JM, Chang RJ, et al: A pharma­
codynamic comparison of human urinary follicle - 
stim ulating hormone and human menopausal 
gonadotropin in normal women and polycystic ovary 
syndrome. Fertil Steril 52:216-229, 1989.
18. Richards JS, Ireland JJ, Rao MC, et al: Ovarian follicu­
lar development in the rat—hormone receptor regula­
tion by estradiol, follicle stimulating hormone and 
luteinizing hormone. Endocrinology 99:1562-1570, 
1976.
19. Dame wood MD, Shen W, Zacur HA, et al: Disappear­
ance of exogenously administered human chorionic 
gonadotropin. Fertil Steril 52:398-400, 1989.
20. Wide L, Johannisson E, Tillinger K-G, et al: Metabolic 
clearance of human chorionic gonadotrophin adminis­
tered to nonpregnant women. Act a Endocrinol (Kbh) 
59:579-594, 1968.
Address reprint requests to: 
Ingrid J,M. Duijlcers, MX).
University Hospital Nijmegen St. Radboud
P.O. Box 9101 
6500 HB Nijmegen, The Netherlands
* •
w
Int J Feitil 40
